Background {#Sec1}
==========

Oligoovulation related to polycystic ovarian syndrome is treated with ovulation induction medications \[[@CR1]\]. These patients have an increased risk of excessive ovarian response which is closely associated with the number of selected follicles \[[@CR2]\]. Therefore, milder protocols have been developed \[[@CR3]\]. In PCOS cases, the estradiol response to gonadotropin treatment is delayed and discordant with the visualized follicular responses \[[@CR3]\]. Androstenedione (A~4~), mostly synthesized in the ovaries is a precursor of E~2~ \[[@CR4], [@CR5]\].

In this study, we aimed to test the hypothesis that the cumulative changes in A~4~ during ovulation induction with low dose rhFSH in PCOS cases are correlated to the number of selected follicles (follicles sized ≥12 mm) comparable to the the cumulative changes in E~2~.

Methods {#Sec2}
=======

This is a prospective case-control study conducted between October 2014 and January 2016. Ethical permission was obtained from the Bagcilar Research and Training Hospital Research Ethics Committee. It was recorded as a prospective case-control study in the [ClinicalTrials.gov](http://clinicaltrials.gov) registry with the identifier NCT02329483. The study was conducted in accordance with the Declaration of Helsinki. Informed consent for participation was obtained from all patients.

Study setting {#Sec3}
-------------

The study was conducted at the Bagcilar Research and Training Hospital Gynecology and Obstetrics Department, Infertility Section. Cycle monitoring was done with folliculometry with transvaginal sonography, E~2,~ P~4~ and A~4~ measurements.

Study population {#Sec4}
----------------

A total of 107 cycles of 61 Control-nonPCOS infertile (Group I) and 46 Study-PCOS infertile (Group II) women were included in the study. The study group was comprised of patients with anti-Müllerian hormone (AMH) levels ≥5 ng/mL (which is equivalent to PCOM (polycystic ovary morphology sonographically confirmed) \[[@CR6]--[@CR8]\]. PCOS was defined as the copresence of at least one of two of the following criteria combined with the PCOM; *(1): oligoamenorrhea-OA*: cycle length \> 35 days, *(2): hyperandrogenism (HA)*: presence of clinical findings including hirsutism defined as the presence of coarse \[long/pigmented\] terminal hair over the most commonly encountered three or more regions within the Modified Ferriman-Gallwey Score System (the buttocks/perineum, sideburn, and neck areas which contributed greatly to the score in the geographic locale where this study was conducted) with or without elevated blood testosterone levels (\>0.5 ng/mL) \[[@CR7]--[@CR12]\]. The control group was comprised of unexplained primary/secondary infertile women with AMH levels \<5 ng/mL, not displaying any clinical findings associated with hyperandrogenism (HA) and with regular menstrual cycles. The inclusion criteria for both groups included ages within 20-35, with normal spermiograms or with mild male factor infertility (i.e.: male partners with only one the following abnormalities: sperm counts being lower than 20 million/ml *or* showing a normal morphology quotient of less than 4% *or* having a sperm motility lower than 40%; *AND* with post-wash total motile sperm counts equal to or higher than 5 million/ml), normal anatomic findings with the hysterosalpingography (no bilateral tubal obstruction or Müllerian anomalies), hormonally eugonadotropic, normal blood prolactin/thyroid-stimulating hormone (TSH) levels and being planned for controlled ovarian hyperstimulation and intrauterine insemination treatment. Exclusion criteria included: diabetes mellitus, BMI \< 20 or \>30, hypo or hypergonadotropism, other causes for hyperandrogenism, ≥2 abortions or ectopic pregnancy, additional medical disorders, ovarian cysts or previous pelvic surgery.

Controlled ovarian hyperstimulation and intrauterine insemination {#Sec5}
-----------------------------------------------------------------

Ovulation induction was conducted with follitropin alpha (Gonal-f Multidose 450 IU; Merck-Serono-Turkey) starting with a dose of 37.5 U/day or 50 U/day as described by Homburg et al. \[[@CR2]\]. Ovulation induction was started on the 3rd or the 4th day of a menstrual cycle having early cycle blood E~2~ levels \<50 pg/mL and blood Progesterone levels \<0.5 ng/mL and in the absence of any ovarian residual follicles larger than 15 mm to rule out the presence of a corpus luteum or any other cystic ovarian structure which could require further clarification. If a primary follicle response characterised by the appearance of a selected growing follicle of ≥10 mm and a rise ≥25% in blood E~2~ levels was not observed despite 14 days of rhFSH stimulation, the initial dose was increased initially to 75 U/day and +37.5 U/day, weekly at each additional incremental step (i.e. 112.5, 150 U/day). Blood E~2~, P~4~, and A~4~ levels were measured and follicle growth was monitored with transvaginal sonography at every visit (every 2-3 days) starting on day 2 or 3 of the cycles. Once 1 or 2 mature follicles ≥18 mm were observed, rhCG (Ovitrelle 150 μg; Merck-Serono-Turkey) s.c. was administered. Sperm washing and intrauterine insemination were carried within \[36th--40th\] hours. On the 15th day postinsemination, blood beta-hCG levels were measured and conception confirmed if the beta-hCG blood level was higher than 20mIU/mL.

Cycle cancellation policy {#Sec6}
-------------------------

Cycle cancellations were due to excessive ovarian responses (more than 2 selected follicles ≥16 mm or blood E~2~ level \> 1500 pg/mL on the rhCG trigger day), no ovarian response despite dose step-up and stimulation for 28-30 days, or premature luteinisation (P~4~ blood level ≥ 1.3 ng/mL).

Laboratory analysis of blood samples {#Sec7}
------------------------------------

Blood samples for hormone measurement were collected from the antecubital vein with a single puncture at every visit during ovulation induction. Samples were collected in a sterile tube and transferred to the lab on the same day. All except the A~4~ blood level measurement results were reported to the physicians on the afternoon of the same day. A~4~ blood levels were available 7-10 days later, and did not provide any guidance to management. A colorimetric ELISA assay (Abcam-USA; Kimera Istanbul-Turkey) was used to measure A~4~ levels. Measurements of AMH were made by using the AMH/MIS enzyme-linked immunosorbent assay. Testosterone values were assayed with the competitive immunoenzymatic colorimetric method. The serum FSH, luteinising hormone (LH), TSH, E~2~, and prolactin levels were measured using a chemiluminescent microparticle immunoassay.

Data analysis {#Sec8}
-------------

Univariate parametric tests were used for group comparisons. Significance was defined as a *P*-value \<0.05. A~4~ (AUC) was calculated as the sum of the areas of trapezoids. Primary A~4~ response during ovulation induction was considered when a rise of ≥25% was observed in the basal A~4~ level. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) Index was calculated for each patient by using an online calculator.

Hierarchial multivariable regression analysis was conducted in both groups to study in a three level linear regression model the contribution of *three sets of independent variables* including the (Model 1) age, BMI and HOMA-IR variables; (Model 2) the E~2~(AUC) values and (Model 3) (the androstenedione related variables: the primary blood androstenedione level and the A~4~ (AUC) values); stepwise, defining *changes in R* ^*2*^ *values (ΔR* ^*2*^) representing the additional effect of each of these newly added independent variable sets, on *the total number of selected follicles*. The SPSS 20.0 and Microsoft Excel 2010 were used.

ROC analysis was performed to define threshold values of the significant determinants of the number of selected follicles to predict cyle cancellations due to excessive ovarian response.

Results {#Sec9}
=======

A total of 107 cycles of infertile women Group I: 61 non-PCOS and Group II: 46 PCOS were followed in 16-months. The PCOS phenotypes were: PCOM (polycystic ovarian morphology:AMH ≥ 5 ng/mL)/OA (oligo/amenorrhea): 4 patients; PCOM/HA (Hyperandrogenism): 27 patients; PCOM/HA/OA: 15 patients. Mild male factor infertility was present in (22/61) 36% of Group I and (15/46) 32.6% in Group II (*P* = 0.5). The HOMA-IR score was ≥4.5 in 6/61 (9,8%) and 9/46 (19,6%) of patients in Groups I and II, respectively. The patient characteristics are summarised in (Table [1](#Tab1){ref-type="table"}). There were 6/61 (9.8%) and 9/46 (19.5%) conceptions in Groups I and II, respectively. The comparison of hormonal characteristics among the conceived and the nonconceived subjects within Groups I and II are summarized in (Table [2](#Tab2){ref-type="table"}). No conception was achieved in the absence of a primary androstenedione response earlier than the primary estradiol response. Cancelled cycles were not included in this comparison.Table 1Cycles analysed in this studyGroup IGroup II(Control Group)(PCOS Group)Age29.8 ± 0.628.7 ± 0.6Duration of infertility (years)3.5 ± 0.33.4 ± 0.4BMI (kg/m^2^)^α^25 ± 0.727.7 ± 0.6AMH(ng/mL)^α^2.4 ± 0.29 ± 0.9HOMA^α^2.8 ± 0.43.8 ± 0.4FSH (mIU/ml)^α^7.2 ± 0.36.3 ± 0.2LH (mIU/ml)^α^6.5 ± 0.59.8 ± 0.6TSH (μIU/mL)2.7 ± 0.23.3 ± 0.7PRL (ng/ml)20.9 ± 1.222 ± 1.9Initial Dose (IU/day)70 ± 4.165 ± 3.7Cycle Length (days)12.2 ± 4.117 ± 0.6Primary follicular/E~2~ response day^α^6.7 ± 0.49.4 ± 0.4EM at trigger day (mm)9.9 ± 0.39.4 ± 0.3Maximum E~2~ (pg/dl)453 ± 42.1556.9 ± 89.3Follicles \>16 mm (n)1.1 ± 0.11.4 ± 0.2Follicles 12-16 mm (n)1.2 ± 0.21.6 ± 0.3Total number of follicles1.9 ± 0.22.2 ± 0.3P~4~ at trigger day (ng/mL)0.7 ± 0.10.8 ± 0.1Day 3 Total Testosterone (ng/mL)^α^0.34 ± 0.280.87 ± 0.3Primary androstenedione level (ng/mL)^α^0.9 ± 0.11.4 ± 0.1Primary androstenedione respond day^α^6.2 ± 0.37.4 ± 0.4Time Lag (A~4~ → E~2~) initial responses (days)^α^0.5 ± 0.42 ± 0.5Maximum A~4~(ng/mL)^α^1.8 ± 0.12.6 ± 0.3Rise in A~4~ (%)^α^66.5 ± 6.984.1 ± 7.4A~4~ (AUC) (ng\*days)^α^3.6 ± 0.35.5 ± 1.3A~4~ on the trigger day (ng/mL)^α^1.3 ± 0.12.5 ± 0.4*PCOS* polycystic ovarian syndrome, *AMH* Anti-Müllerian hormone, *HOMA* homeostasis model for assesment of insulin resistance, *FSH* follicle-stimulating hormone, *LH* luteinising hormone, *TSH* thyroid-stimulating hormone, *E* ~*2*~ estradiol, *PRL* prolactin, *EM* endometrial thickness, *P* ~*4*~ progesterone, *AUC* area under the curve, *A* ~*4*~ androstenedione^α^ *P* \< 0.05 Table 2Comparison of the hormonal characteristics among the conceived and nonconceived subjectsGroup I (Control Group)Group II (PCOS Group)Did not conceiveConceivedDid not conceiveConceivedPrimary A~4~ ^a^0,88 ± 0.450,96 ± 0.21,39 ± 0.081.4 ± 0.33A~4~ (AUC)^b^3,06 ± 2.82.8 ± 1.34,2 ± 0.710.7 ± 7.1E~2~(AUC)^c^1916,6 ± 206.32942.7 ± 1058.42654,2 ± 677.34212.7 ± 767.2AMH^d^2,53 ± 1.23.0 ± 0.419.23 ± 18.6 ± 1.5HOMA-IR^e^3,08 ± 0.32.4 ± 0.63,2 ± 0.342.22 ± 0.33*Time Lag A* ~*4*~ *-E* ~*2*~ *Response*−0,92 ± 0.46−0,67 ± 0.4−0,23 ± 0.11^af^−3.79 ± 0.86^afa^The initial blood androstenedione level (ng/mL)^b^Area under the curve value for Androstenedione (ng\*days)^c^Area under the curve value for estradiol (pg\*days)^d^Antimüllerian hormone (ng/mL)^e^Homeostasis Model for Assessment of Insulin Resistance^f^ *P*\<0.05

Nineteen cycles were cancelled due to excessive response (*n* = 8), no response (*n* = 6), or premature luteinisation (*n* = 5). In those cycles cancelled due to no response, there was no primary A~4~ response.

Univariate analysis revealed that the primary, maximum, and AUC values for A~4~ and the primary blood testosterone levels were all higher in Group II than those in Group I (Table [1](#Tab1){ref-type="table"}).

Plateauing or decreasing A~4~ levels before the trigger day were observed in 33/61 (54,1%) of completed cycles in Group I and 14/46 (30,4%) of cycles in Group II. None of these made any significant difference in the basic characteristics or outcome parameters.

The correlation of A~4~ parameters with the selected follicle numbers and E~2~ (AUC) values are summarised in Figs. ([1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}; and Tables ([3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}): The A~4~(AUC) was correlated with the number of selected follicles and E~2~(AUC) in Group II, but not correlated with any one of these parameters in Group I The primary A~4~ levels were correlated to the primary testosterone levels in both Groups I and II.Fig. 1Correlation of A~4~ related parameters with cycle outcome in Group I Fig. 2Correlation of A~4~ related parameters with cycle outcome in Group II Table 3Correlation of A~4~ parameters with cycle outcome parameters in Group I (Control Group)*R* ^*a*^Primary A~4~increase A~4~%^b^Max A~4~A~4~ AUCFoll 12-16^d^NS0.36^γ^NSNSFoll \>16^c^NSNSNSNSMaximum E~2~NS0.43^γ^NSNS*Total Foll* ^e^ *SelectedNS0.32* ^*γ*^*NSNS*E~2~ = Estradiol; A~4~ = Androstenedione; AUC = Area under the curve; Foll = Number of follicles^γ^ *P* \< 0.005^a^Pearson Correlation constant^b^Percentage rise in the A~4~ level^c^number of follicles \>16 mm^d^number of follicles 12-16 mm^e^number of follicles \>12 mm Table 4Correlation of A~4~ parameters to the cycle outcome parameters in Group II (PCOS Group)*R* ^a^Primary A~4~increase A~4~%^b^Max A~4~A~4~ AUCFoll 12-16^d^0.513^γ^0.446^γ^0.674^γ^0.625^γ^Foll \>16^c^NS0.30.339^γ^0.31^γ^Maximum E~2~0.514^γ^0.512^γ^0.717^γ^0.727^γ^*Total Foll Selected* ^e^*0.542* ^*γ*^*0.5* ^*γ*^*0.73* ^*γ*^*0.673* ^*γ*^E~2~ = Estradiol, A~4~ = Androstenedione, AUC = Area under the curve, Foll = Number of follicles^a^Pearson Correlation constant^b^Percentage rise in the A~4~ level^c^number of follicles \>16 mm^d^number of follicles 12-16 mm^e^number of follicles \>12 mm ^γ^A significant correlation; *P*\<0.05

*Hierarchical multivariable regression analysis* was conducted seperately for *Groups I and II*. The findings of the analysis are summarized in Tables [5](#Tab5){ref-type="table"}(a,b) and [6](#Tab6){ref-type="table"}(a,b). The total number of selected follicles (≥12 mm) was the dependent (outcome) variable. The effect of age, BMI and HOMA-IR on the total number of selected follicles were not significant in either Group I or II. In Group I: the estradiol (AUC) was *the strongest independent factor* (B = 0.0006\[0.0003-0.001\]; *P* \< 0.001), *whereas* in Group II: the A~4~(AUC) (B = 0.114 \[0.04-0.25\]; *P* = 0.01) was *the strongest independent factor effecting the total number of selected follicles.* Table 5Hierarchical multivariable regression analysis of independent variables in Group I (Control Group)Model Summary for Group I(A): Model SummaryModelsChange StatisticsR SquareR Square ChangeF ChangeSig. F Change1^a^0,070,071,1NS2^b^***0,42**0,35**25,4**\<0.001***3^c^0,440,010,5NS(B): CoefficientsModelsCoefficientsBStd. ErrorP1^a^(Constant)3,491,780,06Age0,00040,050,99BMI−0,020,040,59HOMA-IR−0,190,130,152^b^(Constant)−0,461,630,78Age0,060,040,17BMI−0,010,030,75HOMA-IR0,030,110,76*E* ~*2*~ *(AUC)****0,0006**0,0001**\<0.001***3^c^(Constant)−0,501,650,77Age0,060,040,20BMI−0,020,030,66HOMA-IR−0,030,130,83E~2~ (AUC)***0,0006**0,0001**\<0.001***Primary A0,480,490.68A~4~(AUC)0,010,070,85^a^Model 1: including the independent variables Age, BMI, HOMA-IR^b^Model 2: adding the independent variable E2 (AUC) to the previous Model 1^c^Model: adding the independent variables Primary A and A4(AUC) to the previous Model 2 Table 6Hierarchical multivariable regression analysis of independent variables in Group II (PCOS Group)Model Summary for Group 2(A): Model SummaryModelsChange StatisticsR SquareR Square ChangeF ChangeSig. F Change1^a^0,050,050,30.82^b^***0,49**0,44**16,6**\<0.001***3^c^***0,63**0,14**15,1**0.001***(B): CoefficientsModelsCoefficientsBStd. ErrorP1^a^(Constant)5,683,370,10Age−0,050,080,57BMI−0,070,100,50HOMA-IR−0,100,210,642^b^(Constant)6,142,520,02Age−0,060,060,36BMI−0,120,080,13HOMA-IR−0,080,150,62*E* ~*2*~ *(AUC)****0,002**0,001**\<0,01***3^c^(Constant)4,622,430,07Age−0,010,060,89BMI−0,140,070,05HOMA-IR−0,060,140,67E~2~ (AUC)0,00050,00030,34Primary A0,570,600,35A~4~(AUC)***0,114**0,03**0.01***^a^Model 1: including the independent variables Age, BMI, HOMA-IR^b^Model 2: adding the independent variable E2 (AUC) to the previous Model 1^c^Model: adding the independent variables Primary A and A4(AUC) to the previous Model 2

Optimum thresholds for the A~4~ related parameters were defined to predict excessive response within Group II combined were as in Table [7](#Tab7){ref-type="table"}: 88.7%, 3.1 ng/mL and 5.4 ng\*days for the percentage increase in A~4~, the maximum A~4~ value and area under the curve values for A~4~, respectively.Table 7ROC analysis of Androstenedione related parameters (maximum A4, percentage increase in A4 and A4 area under the curve) to define optimum threshold parameters to predict cycle cancellations in Group IIArea Under Curve ± SEM \[5-95p\]Optimum ThresholdSensitivity (%)Specificity (%)A~4~ percentage increase0.73 ± 0.07 \[0.6-0.87\]88.7%7572Maximum A~4~0.78 ± 0.19 \[0.66-0.9\]3.1 ng/mL7574A~4~ (AUC)0.78 ± 0.06 \[0.67-0.9\]5.4 ng\*day7072

Discussion {#Sec10}
==========

In this study, we observed that in PCOS, the cumulative A~4~ response to low-dose rhFSH is a more valid measure of the number of selected follicles than the cumulative Estradiol (E~2~) response \[[@CR13]\].~.~ The early and midfollicular A~4~ variations are more critical determinants than the late follicular variations (following follicle selection), because drops or plateauing observed in A~4~ in the late stages did not influence cycle outcome. The A~4~ respond to rhFSH was earlier than that of E~2~ in cycles with progressive follicular growth and conception.

In six cycles cancelled due to lack of response to rhFSH, there was no A~4~ response. In contrast, in four of the eight cycles cancelled due to excessive response, a dosage step-up had been made due to lack of E~2~response, while there had already been an initial A~4~response. If this corrective information could have been taken into account, an unnecessary step-up could have been avoided.

PCOS is the most common cause of anovulatory infertility, and is reported to comprise 15.3% of the women living in the geographic region where this study was conducted \[[@CR14]\]. PCOS is characterised by three main elements: follicular growth arrest, hyperandrogenism and excessive folliculogenesis \[[@CR15]\].

The chronic low-dose step up protocol used for ovulation induction in PCOS patients requires up to 14 days of rhFSH treatment to overcome a temporary ovarian refractoriness ending with follicle selection \[[@CR16]\]. The follicular growth response initiated by rhFSH in the granulosa cell component when treated with rhFSH is propagated to the theca cell component. During this initial response, in PCOS patients, the reversal of the FSH/LH effect in favour of FSH and aromatisation may not be as hormonally evident with rising E~2~ blood levels as the thecal androgen response, especially at earlier stages. Granulosa cells of the antral follicle at this stage normally respond to this early rise in A~4~ by increasing their aromatase activities, which is strongly counteracted by high AMH levels in the follicular microenvironment of the PCOS follicles, analogous to the AMH-FSH counteraction at later stages of follicular growth \[[@CR17]\]. Thus, the transient follicular growth arrest is observed at this early stage due to the AMH-androgen counteraction \[[@CR18], [@CR19]\]. High androgen and AMH concentrations also contribute to the microenvironment that fosters excessive folliculogenesis and follicular growth arrest \[[@CR11], [@CR20]--[@CR23]\].

Basal androgen blood levels measured at the beginning or during induction cycles have been reported in various studies in low responders, patients with diminished ovarian reserves, or normal responders, but not in PCOS cases. Ferrario et al. showed in a group of older women with low response that A~4~ levels measured at the beginning of IVF cycles were predictors of positive outcome \[[@CR24]\]. Similarly, Sun et al. have shown in a study of 1413 infertile women going through their first cycle of IVF that the testosterone blood levels measured at the beginning of the treatment cycles were predictors of the number of follicles larger than 14 mm on the day of hCG trigger, but were not predictors of conception \[[@CR25]\]. It would be interesting and supplementary to monitor the testosterone response to rhFSH during ovulation induction cycles in prospective observational studies.

Our study had some *potential causes of bias and limitations* which need to be addressed. From the perspective of the Rotterdam 2003 definition of PCOS, cases with the nonPCOM/HA/OA (defined as phenotype B) may be being underrepresented in the infertile PCOS patients group (Group II) \[[@CR26]\]. Another limitation was that the BMI's in *Group II* were slightly, but significantly higher than *Group I*. However, in the hierarchical multivariable regression conducted, BMI as well as age and HOMA-IR were included in a separate model and their effects on the total number of selected follicles were found to be insignificant in both *Groups I and II*.

Conclusion {#Sec11}
==========

The findings in this clinical study suggest that the reactive rise in androstenedione in the early follicular phase is a better predictor of the number of follicles selected than the conventionally used reactive rise in estradiol in PCOS cases. The longer/higher is the increase in its blood levels, the more are the follicles joining the growing cohort with an increasing risk of excessive ovarian response. On the other hand, androstenedione is an earlier and more reliable marker of the initial ovarian response to gonadotropins and this earlier response may be essential for progressive follicle growth and possibly a conception in an ovulation induction and intrauterine insemination cycle (using rhFSH) in PCOS. It still needs to be further studied in prospective studies encompassing induction cycles managed mainly with A~4~ monitoring, to provide stronger evidence if androstenedione monitoring provides a more valid and useful information to indicate ovarian response and if an earlier androstenedione response is associated with conception.

A4

:   Androstenedione

AMH

:   Antimüllerian hormone

AUC

:   Area under the curve

beta-hCG

:   beta human chorionic gonadotroopin

BMI

:   Body mass index

E2

:   Estradiol.

FSH

:   Follicle stimulating hormone

HA

:   Hyperandrogenism

HOMA-IR

:   Homeostatic model assessment of insulin resistance

IVF

:   In vitro fertilization

OA

:   Oligo/amenorrhea

P4

:   Progesterone

PCOM

:   polycystic ovarian morphology

PCOS

:   Polycystic ovary syndrome

rhFSH

:   Recombinant human follicle stimulating hormone

ROC

:   Receiver operating curve

TSH

:   Thryoid stimulating hormone

Not applicable.

Funding {#FPar1}
=======

The Funding of the study was provided by the Bagcilar Research and Training Hospital Education Planning Committee.

Availability of data and materials {#FPar2}
==================================

The dataset supporting the conclusion of this article is included within the article.

Authors' contributions {#FPar3}
======================

SEO conceptualized and suggested a plan for the study. TY then joined the study group and helped improve the plan and theoretically better defined the study plan and its connotations of possible results. With contribution of GA the study was started. The data collection and input was carried out by SEO and GA. The data analysis and manuscript writing was done by SEO and the manuscript read and approved by the three authors.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Ethics approval and consent to participate {#FPar5}
==========================================

All women gave their informed consent. The study was reviewed and approved by the Ethics Commitee of the Bagcilar Training and Research Hospital (2015/312). All patients gave informed consent for participating in this study.

Publisher's note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
